Get the Stockscreener App
0.8544
3.83%
-0.0256
After Hours:
.85
-0.0044
-0.51%
Revelation Biosciences Inc stock is traded at $0.8544, with a volume of 455.60K.
It is down -3.83% in the last 24 hours and down -72.25% over the past month.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
See More
Previous Close:
$0.88
Open:
$0.8802
24h Volume:
455.60K
Relative Volume:
2.87
Market Cap:
$820.70K
Revenue:
-
Net Income/Loss:
$-15.52M
P/E Ratio:
-0.046
EPS:
-18.58
Net Cash Flow:
$-16.61M
1W Performance:
-65.17%
1M Performance:
-72.25%
6M Performance:
-93.04%
1Y Performance:
-96.79%
1-Day Range:
$0.839
$0.90
1-Week Range:
$0.83
$2.50
52-Week Range:
$0.83
$60.80
Revelation Biosciences Inc Stock (REVB) Company Profile
Name
Revelation Biosciences Inc
Sector
Industry
Phone
650-800-3717
Address
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
0.8549 | 2.50M | 0 | -15.52M | -16.61M | -18.58 |
|
ONC
Beone Medicines Ltd Adr
|
245.60 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.01 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.22 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.80 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Revelation Biosciences Inc Stock (REVB) Latest News
Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering - Insider Monkey
Revelation Biosciences sets terms for $4 million public offering By Investing.com - Investing.com Canada
Revelation Biosciences, Inc. Announces Closing Of $4 Million Public Offering - marketscreener.com
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering - Business Wire
REVB stock touches 52-week low at $0.86 amid sharp annual decline - Investing.com Canada
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering - BioSpace
Revelation Biosciences Announces Pricing Of $4 Million Public Offering - marketscreener.com
Revelation Biosciences sets terms for $4 million public offering - Investing.com Australia
Revelation Biosciences announces pricing of $4M public offering - MSN
Revelation Biosciences Board Member Resigns Amid New Role - TipRanks
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Revelation Biosciences board member steps down amid new focus - Investing.com Australia
Revelation Biosciences board member steps down amid new focus By Investing.com - Investing.com Canada
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors - The Joplin Globe
REVB: New Market Potential and Quarterly Results - Research Tree
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025 - BioSpace
Revelation Biosciences (REVB) Projected to Post Earnings on Friday - Defense World
Allergic Rhinitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, - openPR.com
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients - BioSpace
REVB: New Target Market Announced - Research Tree
Peripheral Blood Mononuclear Cells Market Size to Hit USD 774.41 Bn by 2034 - Precedence Research
Why Revelation Biosciences Inc. (REVB) Went Down On Thursday? - Insider Monkey
Pre-market Movers: IBO, ALUR, GCTK, TELA... - RTTNews
Revelation Biosciences (REVB) to Release Earnings on Friday - Defense World
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics - GlobeNewswire
REVB stock touches 52-week low at $2.71 amid sharp annual decline - Investing.com
REVB stock touches 52-week low at $2.71 amid sharp annual decline By Investing.com - Investing.com South Africa
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Revelation Biosciences: Gemini priming attenuates inflammatory response in PBMCs - TipRanks
Gemini Priming Attenuates Inflammation In Human Peripheral Blood Mononuclear Cells - Marketscreener.com
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells - Business Wire
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference - Business Wire
What is Roth Capital’s Estimate for REVB FY2029 Earnings? - Defense World
REVB: 2025 Is the Year for Measurable Progress - Research Tree
Revelation Biosciences Inc. (REVB) reports earnings - Quartz
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 - WICZ
Revelation Biosciences stock hits 52-week low at $3.26 By Investing.com - Investing.com South Africa
Revelation Biosciences stock hits 52-week low at $3.26 - Investing.com
Revelation Biosciences Doses First Patient In Prime Phase 1B Clinical Study Of Gemini In CKD Patients - Marketscreener.com
Revelation doses first patient in PRIME Phase 1b clinical study - TipRanks
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Business Wire
Artificial Intelligence (AI) News Live Feed - StockTitan
Revelation Biosciences gets continued listing approval from Nasdaq - MSN
Revelation Biosciences Says Regained Compliance With Nasdaq Minimum Bid Price Requirement - marketscreener.com
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval - Business Wire
Revelation Biosciences Inc Stock (REVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):